8-K: 2seventy bio Announces Abecma Revenue and FDA Advisory Committee Meeting

2seventy bio reported $56 million in U.S. revenue for Abecma in Q4 2023 and announced an upcoming FDA advisory committee meeting to review its expanded use.

Summary

• 2seventy bio announced that Abecma generated approximately $56 million in U.S. revenue during the fourth quarter of 2023.
• The company shares profits and losses equally with Bristol Myers Squibb (BMS) for Abecma's development, manufacturing, and commercialization in the U.S.
• This revenue figure is based on unaudited information provided by BMS and does not represent the full financial picture for 2seventy bio.
• The company expects to release its full financial results for the quarter and year ended December 31, 2023, on or before April 1, 2024.
• The U.S. Food and Drug Administration (FDA) will convene a virtual meeting of the Oncologic Drugs Advisory Committee (ODAC) on March 15, 2024, to review data supporting the supplemental Biologics License Application (sBLA) for Abecma.
• The ODAC review will focus on data related to the secondary endpoint of overall survival from the pivotal Phase 3 KarMMa-3 study for triple-class exposed relapsed or refractory multiple myeloma.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the solid revenue figure and the upcoming FDA review, but there are also risks and uncertainties associated with regulatory approvals and commercial success.

Positives

• Abecma's revenue of $56 million in Q4 2023 indicates strong sales performance.
• The upcoming ODAC meeting provides an opportunity for Abecma to expand its approved use.
• Abecma's approval in Japan and positive opinion from the EMA demonstrate its global potential.
• The KarMMa-3 study data is being reviewed for a potential label expansion.

Negatives

• The $56 million revenue figure is unaudited and may not reflect the final results.
• The full financial results for the quarter and year are not yet available.
• The ODAC review introduces uncertainty regarding the potential approval of the sBLA.

Risks

• The ODAC review may not result in a positive recommendation for Abecma's sBLA.
• Regulatory applications for Abecma are still under review with the EMA and Swissmedic.
• The commercial success of Abecma is not guaranteed.
• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

The company anticipates the ODAC will review data related to the secondary endpoint of overall survival from the KarMMa-3 study. The company expects to announce its full results for the quarter and year ended December 31, 2023 on or before April 1, 2024.

Management Comments

• The company and BMS share equally in all profits and losses related to development, manufacture and commercialization of Abecma in the U.S.

Industry Context

This announcement is significant in the context of the growing CAR T-cell therapy market, particularly for multiple myeloma. The FDA review and potential label expansion for Abecma could further solidify its position in this competitive landscape. The approval in Japan and positive opinion from the EMA also highlight the global interest in this therapy.

Comparison to Industry Standards

• Abecma's $56 million in quarterly revenue is a significant figure in the CAR T-cell therapy space, though direct comparisons are difficult without full financial results from competitors.
• Companies like Gilead (Yescarta) and Novartis (Kymriah) are key competitors in the CAR T-cell therapy market, and their revenue figures are important benchmarks.
• The KarMMa-3 study results are being compared to other clinical trials in multiple myeloma to assess the efficacy and safety of Abecma.
• The regulatory approvals in Japan and the positive opinion from the EMA are important milestones, placing Abecma in a competitive position with other CAR T-cell therapies seeking global approvals.

Related Party Transactions

• The company and Bristol Myers Squibb share equally in all profits and losses related to development, manufacture and commercialization of Abecma in the U.S.

Stakeholder Impact

• Shareholders will be interested in the revenue figures and the outcome of the FDA review.
• Patients with multiple myeloma may benefit from the potential expanded use of Abecma.
• Employees of 2seventy bio and Bristol Myers Squibb are involved in the development and commercialization of Abecma.
• The company's financial performance impacts its suppliers and creditors.

Next Steps

• The FDA's ODAC will review the sBLA for Abecma on March 15, 2024.
• 2seventy bio will announce its full financial results for the quarter and year ended December 31, 2023 on or before April 1, 2024.
• The company will continue to work with regulatory agencies for approvals in other regions.

Key Dates

Keywords

Abecma, 2seventy bio, Bristol Myers Squibb, multiple myeloma, CAR T cell therapy, FDA, ODAC, KarMMa-3, revenue, sBLA, oncology, cell therapy